RSV denials in California external review
In the California DMHC record, independent physician reviewers decided 22 published external-review cases involving rsvand overturned the plan’s denial in 59.1%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Most-fought treatments for rsv
| Category | Decisions | Overturned |
|---|---|---|
| Anti-virals | 6 | 66.7% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 19 | 52.6% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 100% |
What the reviewers wrote
Where the denial was overturned
The parent of an eight-month-old male enrollee has requested for a Synagis injection for treatment of the enrollee’s respiratory distress syndrome with respiratory failure. Findings: The physician reviewer found that The American Academy of Pediatrics (AAP) guidelines published in 2003 recommend palivizumab for RSV prophylaxis for premature infants born at 32 to 35 weeks gestation who are six months old or younger at the start of RSV season if they possess two additional risk factors. These factors include school-age siblings, day care attendance, airway abnormalities, neuromuscular disease and/or exposure to environmental air pollutants.Horn and Stout analyzed retrospective data from 304 infants less than one year of age with bronchiolitis or RSV pneumonia admitted to the hospital.
The parent of a one-year-old female enrollee has requested Synagis injections for treatment of the enrollee’s risk of contracting respiratory syncytial virus. Findings: The physician reviewer found that there are a number of risk factors that increase the chance of morbidity from RSV disease in prematurely born infants, up to 12 months of age. The most striking of these complications is a birth weight of less than 2500 grams. Further, Holman and colleagues caution that an infant with a birth weight less than 1500 grams is 25 times more likely to develop complications with the RSV infection than an infant with a birth weight greater than 2500 grams.
Where the denial was upheld
The parent of a five-month-old female enrollee has requested Synagis for treatment of the enrollee’s prematurity to protect against respiratory syncytial virus (RSV). Findings: The physician reviewer found that the American Academy of Pediatrics (AAP), the Centers for Disease Control (CDC), and the American Committee on Immunization Practices, have invested a substantial amount of resources into determining which infants would most likely benefit from treatment with palivizumab (Synagis). The current recommendations are based on the evidence that demonstrates which children are most likely to be hospitalized with RSV. The majority of infants who are hospitalized with RSV have multiple risk factors, including prematurity and lung disease and/or heart disease.
The parent of a five-month-old female enrollee has requested Synagis for treatment of the enrollee’s prematurity to protect against respiratory syncytial virus (RSV). Findings: The physician reviewer found that the American Academy of Pediatrics (AAP), the Centers for Disease Control (CDC), and the American Committee on Immunization Practices, have invested a substantial amount of resources into determining which infants would most likely benefit from treatment with palivizumab (Synagis). The current recommendations are based on the evidence that demonstrates which children are most likely to be hospitalized with RSV. The majority of infants who are hospitalized with RSV have multiple risk factors, including prematurity and lung disease and/or heart disease.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving rsv, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY